NASDAQ:KNSY - Kensey Nash Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Kensey Nash logoKensey Nash Corporation is a medical device company primarily focused in the field of regenerative medicine, which is the application of devices, materials and other therapies to help repair damaged or diseased tissues. The Company has a range of products, which are sold through strategic partners in multiple large medical markets, including cardiology, orthopaedic, sports medicine, spinal and general surgery. It also has an ongoing development and manufacturing program for products in the endovascular market. During the fiscal year ended June 30, 2010 (fiscal 2010), the Company manufactured and sold over 4.5 million resorbable product units representing approximately 230 commercialized products, to strategic partners and customers. In January 2011, the Company acquired Nerites Corporation. In June 2012, Koninklijke DSM NV acquired the Company.

Receive KNSY News and Ratings via Email

Sign-up to receive the latest news and ratings for KNSY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:KNSY
CUSIPN/A
Phone+1-484-7132100

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A
Market Cap$0.00

The Truth About Cryptocurrencies

Kensey Nash (NASDAQ:KNSY) Frequently Asked Questions

What is Kensey Nash's stock symbol?

Kensey Nash trades on the NASDAQ under the ticker symbol "KNSY."

What is the consensus analysts' recommendation for Kensey Nash?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kensey Nash in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."

Has Kensey Nash been receiving favorable news coverage?

News stories about KNSY stock have trended somewhat positive recently, Accern reports. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Kensey Nash earned a media sentiment score of 0.13 on Accern's scale. They also assigned news headlines about the medical device company an impact score of 46.38 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.

How do I buy shares of Kensey Nash?

Shares of KNSY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Kensey Nash?

Kensey Nash's mailing address is 735 Pennsylvania Drive, EXTON, PA 19341, United States. The medical device company can be reached via phone at +1-484-7132100.


MarketBeat Community Rating for Kensey Nash (NASDAQ KNSY)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  44 (Vote Outperform)
Underperform Votes:  57 (Vote Underperform)
Total Votes:  101
MarketBeat's community ratings are surveys of what our community members think about Kensey Nash and other stocks. Vote "Outperform" if you believe KNSY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KNSY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.